Analyzing...
Loading company...
Sanofi India Ltd. engages in the manufacturing and distribution of pharmaceutical drugs. The company is headquartered in Mumbai, Maharashtra and currently employs 3,530 full-time employees. The firm is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The company offers a range of medicines and supplements for treatment of diabetes (both insulin and orals), cardiology, thrombosis, epilepsy, allergies, and infections. The company has two manufacturing sites, one in Hyderabad and one in Goa. Its geographical segments include India, Singapore, and Others. The company sells its products through independent distributors primarily in India. The company also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), eye/ear drops, ampoules, vials, creams, and ointment. Its brands include Lantus, Allegra, and Combiflam. Its vaccine products include Adacel, Avaxim 80U/160U, FluQuadri, Hexaxim, Menactra, Tetraxim, Vaxigrip, Stamaril, Shanvac-B and ShanTT. Its consumer healthcare products include Allegra, Allegra nasal, and Avil.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹2,013 Cr revenue.
COGS 48.6%, employees 11.9%.
“Without the replenishment issues at the partner level, the combined growth would have been significantly higher, potentially reaching double digits for the quarter.”
“Export is around 12-13% of total sales. Export drop significant in top line but only 8% impact on profit before tax”
“operating margin, we in this quarter are under 28%”
Historical valuation data not available.
| (₹ Cr) | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | ₹2,235 Cr +11.0% | ₹2,013 Cr -29.4% | ₹2,851 Cr |
| Other Income | ₹20 Cr +18.2% | ₹17 Cr -74.7% | ₹65 Cr |
| Total Income | ₹2,254 Cr +11.1% | ₹2,030 Cr -30.4% | ₹2,916 Cr |
| COGS | ₹1,039 Cr +6.1% | ₹979 Cr -18.5% | ₹1,201 Cr |
| ₹1,701 Cr +9.0% | ₹1,561 Cr -25.3% | ₹2,089 Cr | |
| Profit Before Tax | ₹515 Cr +19.4% | ₹431 Cr -49.0% | ₹846 Cr |
| Exceptional Items | (₹38 Cr) 0.0% | (₹38 Cr) ↓ Decline | ₹18 Cr |
| ₹137 Cr +16.4% | ₹118 Cr -51.5% | ₹243 Cr | |
| Net Profit | ₹378 Cr +20.6% | ₹314 Cr -48.0% | ₹603 Cr |
| Profit (Owners) | ₹413 Cr -0.0% | ₹413 Cr -31.4% | ₹603 Cr |
| Other Comprehensive Income | ₹7 Cr 0.0% | ₹7 Cr ↑ Recovery | (₹1 Cr) |
| EPS | ₹179.45 | ₹179.46 | ₹261.78 |
| Diluted Shares | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| Profit Loss From Discontinued Operations After Tax | ₹35 Cr -64.9% | ₹100 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Sanofi India Limited has informed the Exchange about change in Senior Management Personnel Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2...
Sanofi India Limited has informed the Exchange about Resignation of Director/KMP/SMP
Sanofi India Limited has informed the Exchange about Schedule of meet
Sanofi India Limited has informed the Exchange regarding Resignation of Mr Rachid Ayari as Whole Time Director and Chief Financial Officer of the Company w.e.f. September 30, 2026.
Sanofi India Limited has informed the Exchange regarding resignation of Mr Rachid Ayari as Chief Financial Officer of the Company with effect from the close of business hours on 30th September 2026
Sanofi India Limited has informed the Exchange about change in Management
Sanofi India Limited has informed the Exchange regarding Change in Director(s) of the company.
Please find enclosed certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June 2026.
Sanofi India Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulatio...
Sanofi India Limited has informed the Exchange about appointment of Mr. Debajit Roy as Sales & Customer Engagement Head Diabetes of the Company.
Please find enclosed intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Sanofi India Limited has informed the Exchange about Copy of Newspaper Publication regarding the information on special window for transfer and dematerialisation of physical shares.
Sanofi India Limited has informed the Exchange regarding a press release dated April 30, 2026, titled "Please find enclosed Press Release dated 30th April 2026.".
Sanofi India Limited has informed the Exchange about the Newspaper Advertisement regarding 70th Annual General Meeting and Opening of another Special Window for re-lodgement of transfer requests of ph...
Please find enclosed disclosure received under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015